Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Today and Tomorrow: Managing Resistance in Heavily ART-Experienced People with HIV

Premiere Date: Friday, December 9, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Saturday, December 9, 2023
Note: Credit Is No Longer Available


David Alain Wohl, MDDavid Alain Wohl, MD (Moderator)
Professor of Medicine
Institute of Global Health and Infectious Diseases
Site Leader, Global Infectious Diseases Clinical Trials Unit, Chapel Hill Site
The University of North Carolina (UNC) at Chapel Hill School of Medicine
Chapel Hill, NC

Sorana Segal-Maurer, MDSorana Segal-Maurer, MD 
Director, The Dr. James J. Rahal Jr. Division of Infectious Diseases
NewYork-Presbyterian Queens
Professor of Clinical Medicine
Weill Cornell Medical College
Cornell University
New York, NY

Statement of Need

The use of antiretroviral (ARV) medication therapies has led to successful treatment for many patients with HIV. However, antiretroviral therapy (ART) resistance and medication adherence problems can reduce the chances of treatment success.1,2 Health care professionals (HCPs) need up-to-date education on the causes of ART resistance and non-adherence for patients who are treatment-experienced, as well as the treatment alternatives available including new ARV therapies with varying mechanisms of delivery (e.g., oral vs. injections). With this education, HCPs will be better prepared to treat patients with HIV who are treatment-experienced, reducing or mitigating the problems of ART treatment resistance and medication non-adherence.

In this CMEOCast podcast, expert faculty will present the latest information on the causes of ART resistance and medication non-adherence in patients with HIV and discuss the latest medication therapies that may prevent or counter treatment resistance and non-adherence, especially in patients who are treatment-experienced.

  • World Health Organization (WHO). WHO fact sheet: HIV drug resistance. WHO Website. Published November 18, 2020. Accessed June 2, 2021.
  • Benson C, Wang X, Dunn, KJ, et al. Antiretroviral adherence, drug resistance, and the impact of social determinants of health in HIV-1 patients in the US. AIDS Behav. 2020;24(12):3562-3573.
  • Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Identify the etiology of ARV treatment resistance to improve HCPs’ competence in assessing and managing HIV in individuals who are heavily treatment experienced.
    • Apply efficacy and safety data for current and new ARV treatments that minimize risk of treatment resistance in treatment-experienced patients with HIV.
    • Evaluate efficacy and safety data for new and emerging long-acting oral and injectable ART regimens for heavily treatment-experienced people with HIV, including individuals with ARV resistance.

    Financial Support

    Supported by an educational grant from Gilead Sciences, Inc. This educational activity is supported by an independent educational grant from ViiV Healthcare.

    ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

    Target Audience

    PAs, NPs, nurses, pharmacists, primary care physicians and physicians specializing in infectious disease

    Credit Information

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    MIPS Improvement Activity:
    This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

    Royal College MOC
    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Disclosure Declaration

    It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

    Dr. Wohl reports the following financial relationships:

    Advisory Board: Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Theratechnologies Inc.; and ViiV Healthcare

    Consultant: Gilead Sciences, Inc.; and Janssen Pharmaceuticals, Inc.

    Grants and Research Support: Eli Lilly and Company; Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare

    Dr. Segal-Mauer reports the following financial relationships:

    Consultant: Gilead Sciences, Inc. and Janssen Pharmaceuticals, Inc.

    Speakers Bureau: Gilead Sciences, Inc. and Janssen Pharmaceuticals, Inc.

    The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Mary Gleason (planning committee)
  • Kellie Busby, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download